VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology is pleased to announce that it has received approval to upgrade from the OTC Pink Market to the OTCQB® Venture Market (the “OTCQB“).

Core One Labs’ Upgrades to OTCQB Venture Market
- Post published:April 6, 2022
- Post category:Press Release
Tags: Core One Labs
You Might Also Like

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials
